Molecular Expression Analysis of Restrictive Receptor for Interleukin 13, a Brain Tumor-associated Cancer/Testis Antigen

Molecular Medicine

Volumn 6, Issue 5, 2000, Pages 440-449

  Debinski, Waldemar ^a   Gibo, Denise M ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Human IL 1ra; IL 2Ra Gene Expression; IL13 Binding Sites; Interleukin (IL13); Restricted Receptor

Indexed keywords

IL13RA1 PROTEIN, HUMAN; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN RECEPTOR; PROTEIN SUBUNIT;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; BRAIN; BRAIN TUMOR; CELL CULTURE; CELL LINE; FETUS; GENETIC TRANSCRIPTION; GENETICS; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNOLOGY; MALE; REFERENCE VALUE; TESTIS;

ADULT; BRAIN; BRAIN NEOPLASMS; CELL LINE; FETUS; GLIOBLASTOMA; GLIOMA; HUMANS; INTERLEUKIN-13; INTERLEUKIN-13 RECEPTOR ALPHA1 SUBUNIT; MALE; ORGAN SPECIFICITY; PROTEIN SUBUNITS; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-13; RECEPTORS, INTERLEUKIN-4; REFERENCE VALUES; TESTIS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

MLCS; MLOWN;

EID: 0034184409     PISSN: 10761551     EISSN: 15283658     Source Type: Journal    
DOI: 10.1007/BF03401786     Document Type: Article

References (28)

1. W. Debinski D. Gibo S.W. Hulet J.R. Connor G.Y. Gillespie Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas Clin. Cancer Res. 1999 5 985 990 10353730 1:CAS:528:DyaK1MXjslKltL8%3D
2. A.N.J. McKenzie J.R. Culpepper R. De Waal Malefyt et al. Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function Proc. Natl. Acad. Sci. 1993 90 3735 3739 10.1073/pnas.90.8.3735 1:CAS:528:DyaK3sXktVKqt7w%3D 8097324
3. A. Minty P. Chalon J.M. Derocq et al. In-terleukin-13 is a new human lymphokine regulating inflammatory and immune responses Nature 1993 36 248 251 10.1038/362248a0
4. W. Debinski N.I. Obiri I. Pastan R.K. Puri A novel chimeric protein composed of inter-leukin 13 and Pseudomonas exotoxin is highly cy-totoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4 J. Biol. Chem. 1995 270 16775 16780 10.1074/jbc.270.28.16775 1:CAS:528:DyaK2MXmvFOktL8%3D 7622490
5. N.I. Obiri P. Leland T. Murata W. Debinski R.K. Puri The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor J. Immunol. 1997 158 756 764 8992992 1:CAS:528:DyaK2sXmtFGlsA%3D%3D
6. D.J. Hilton J.-G. Zhang D. Metcalf W.S. Akexander N.A. Nicola T.A. Wilson Cloning and characterization of a binding subunit of the in-terleukin 13 receptor that is also a component of the interleukin 4 receptor Proc. Natl. Acad. Sci. U.S.A. 1996 93 497 501 10.1073/pnas.93.1.497 1:CAS:528:DyaK28Xjslykug%3D%3D 8552669 40265
7. R.L. Idzerda C.J. March B. Mosley et al. Human interleukin-4 receptor confers biological responsiveness and defines a novel receptor su-perfamily J. Exp. Med. 1990 171 861 873 10.1084/jem.171.3.861 1:CAS:528:DyaK3cXltFenu74%3D 2307934
8. W. Debinski N.I. Obiri S.K. Powers I. Pastan R.K. Puri Human glioma cells over-express receptor for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin Clin. Cancer Res. 1995 1 1253 1258 9815919 1:CAS:528:DyaK28XjvF2htw%3D%3D
9. W. Debinski R. Miner P. Leland N.I. Obiri R.K. Puri Receptor for IL 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells J. Biol. Chem. 1996 271 22428 22433 10.1074/jbc.271.37.22428 1:CAS:528:DyaK28Xlslaitbk%3D 8798406
10. W. Debinski An immune regulatory cy-tokine and high-grade gliomas: An unexpected link Critic. Rev. Oncogen. 1998 9 256 268
11. D. Caput P. Laurent M. Kaghad et al. Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor ± chain J. Biol. Chem. 1996 271 16921 16926 10.1074/jbc.271.28.16921 1:CAS:528:DyaK28Xkt1Cjtrs%3D 8663118
12. W. Debinski D.M. Gibo N.I. Obiri A. Kealiher R.K. Puri Novel anti-brain tumor cytotox-ins specific for cancer cells Nature Biotech. 1998 16 449 453 10.1038/nbt0598-449 1:CAS:528:DyaK1cXjtV2jt7o%3D
13. J. Thompson W. Debinski Mutants of in-terleukin 13 with altered reactivity toward IL13 receptors J. Biol. Chem. 1999 274 29944 29950 10.1074/jbc.274.42.29944 1:CAS:528:DyaK1MXmvVajtrw%3D 10514477
14. D.W. Laske R.J. Youle E.H. Oldfield Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors Nature Med. 1997 3 1362 1368 10.1038/nm1297-1362 1:CAS:528:DyaK2sXnvVGisrw%3D 9396606
15. P. Chomczynski N. Sacchi Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction Anal. Biochem. 1987 162 156 159 10.1016/0003-2697(87)90021-2 1:CAS:528:DyaL2sXitFSns7Y%3D 2440339
16. J. Guo F. Apiou M.-P. Mellerin B. Lebeau Y. Jacques S. Minvielle Chromosome mapping and expression of the human inter-leukin-13 receptor Genomics 1997 42 141 145 10.1006/geno.1997.4628 1:CAS:528:DyaK2sXjt12ku7k%3D 9177784
17. B. Schnyder S. Lugli N. Feng et al. Inter-leukin-4 (IL-4) and IL-13 bind to a shared het-erodimeric complex on endothelial cells mediating vascular cell adhesion molecule-1 induction in the absence of the common 7 chain Blood 1996 87 4286 4295 8639787 1:CAS:528:DyaK28XivFGhtbg%3D
18. W. Debinski J. Thompson Retargeting in-terleukin 13 for radioimmunodetection and redioimmunotherapy of human high-grade glio-mas Clin. Cancer Res. 1999 5 3143s 3147s 10541355 1:CAS:528:DyaK1MXnsVShtrg%3D
19. U. Sahin O. Tureci H. Schmitt et al. Human tumors elicit multiple specific immune response in autologous host Proc. Natl. Acad. Sci. 1995 92 11810 11813 10.1073/pnas.92.25.11810 1:CAS:528:DyaK2MXpvVOnt7w%3D 8524854
20. O. Tureci U. Sahin C. Zwick M. Koslowski G. Seitz M. Pfreundschuh Identification of a meiosis-specific protein as new member of 449 the cancer/testis antigen superfamily Proc. Natl. Acad. Sci. 1998 95 5211 5216 10.1073/pnas.95.9.5211 1:CAS:528:DyaK1cXivV2jtrk%3D 9560255
21. M.J. Scanlan J. Gordan B. Williamson et al. Antigens recognized by autologous antibody in patients with renal-cell carcinoma Int. J. Cancer 1999 83 456 464 10.1002/(SICI)1097-0215(19991112)83:4<456::AID-IJC4>3.0.CO;2-5 1:CAS:528:DyaK1MXntlWks78%3D 10508479
22. O. Tureci U. Sahin C. Zwick F. Neumann M. Pfreundschuh Exploitation of the antibody repertoire of cancer patients for the identification of human tumor antigens Hybridoma 1999 18 23 28 10.1089/hyb.1999.18.23 1:CAS:528:DyaK1MXit1ahs7c%3D 10211784
23. S.A. Rosenberg J.C. Yang D.J. Schwartzentruber et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma Nature Med. 1998 4 321 327 10.1038/nm0398-321 1:CAS:528:DyaK1cXhs1Kju7c%3D 9500606
24. M.S. Mahaley W.H. Brooks T.L. Roszman D.D. Bigner L. Duka S. Richardson Immunobiol-ogy of primary intracranial tumors J. Neurosurg. 1977 46 467 476 10.3171/jns.1977.46.4.0467 191575
25. D.L. Scarcella C.W. Chow M.F. Gonzales C. Economou F. Brasseur D.M. Ashley Expression of MAGE and GAGE in high-grade brain tumors: A potential target for specific im-munotherapy and diagnostic markers Clin. Cancer Res. 1999 5 335 341 10037183 1:CAS:528:DyaK1MXhsVWrt7g%3D
26. F.G. Davis S. Freels J. Grutsch S. Barlas S. Brem Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973–1991 J. Neurosurgery 1998 88 1 10 10.3171/jns.1998.88.1.0001 1:STN:280:DyaK1c%2FotVagsQ%3D%3D
27. S.A. Rosenberg A new era for cancer im-munotherapy based on the genes that encode cancer antigens Immunity 1999 10 281 287 10.1016/S1074-7613(00)80028-X 1:CAS:528:DyaK1MXitlamtrs%3D 10204484
28. A. Mintz W. Debinski Cancer genet-ics/epigenetics and the X chromosome: Possible new links for malignant glioma pathogen-esis and immune-based therapies Crit. Rev. Oncogen 2000 11 77 95 10.1615/CritRevOncog.v11.i1.40 1:CAS:528:DC%2BD3cXjtFSgtbs%3D